Sonova Stock - analyst consensus and outlook for the hearing-aid group

Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 03:02 CET. Details in the imprint.

Sonova (CH0012549785) starts the new week with investors reviewing analyst expectations and the company’s latest guidance for the current fiscal year. The Swiss hearing-aid specialist last updated its outlook alongside full-year results released on 05/21/2024, according to the company’s investor relations material.

What recent guidance shows

In its 2023-24 annual results, Sonova reported sales of CHF 3.97 billion, up around 7% in local currencies, and an adjusted EBITA margin of about 26%, according to the company’s results presentation.

The group guided for organic sales growth in the mid-single-digit to high-single-digit percentage range for 2024-25 and a slight improvement in the adjusted EBITA margin, as outlined in the full-year outlook on its investor page.

Analyst views and consensus

According to consensus data compiled by financial portals, most analysts rate Sonova between Hold and Buy, with a majority in the positive camp and only a small minority on the sell side.

Average 12-month price targets in those surveys typically imply mid- to high-single-digit percentage upside from recent trading levels, although individual targets vary significantly depending on margin and growth assumptions.

What the week could bring

This week does not feature a scheduled Sonova earnings release, but investors will watch macro data and peer news from hearing-care and medtech names for read-across to demand trends.

Any updates on reimbursement frameworks, regulatory decisions in key markets, or large M&A moves in the sector could also influence how the market prices Sonova’s growth profile and valuation multiples.

How Sonova makes its money

Sonova generates most of its revenue from hearing instruments and related audiological services, complemented by cochlear implants and consumer hearing devices sold under brands such as Phonak and Unitron through clinics, retail networks and specialist partners worldwide.

Where the stock trades today

The shares of Sonova (CH0012549785) trade on SIX Swiss Exchange at CHF 250.00 as of 06/21/2026, 17:30 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.